BR0015963A - Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos - Google Patents

Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos

Info

Publication number
BR0015963A
BR0015963A BR0015963-8A BR0015963A BR0015963A BR 0015963 A BR0015963 A BR 0015963A BR 0015963 A BR0015963 A BR 0015963A BR 0015963 A BR0015963 A BR 0015963A
Authority
BR
Brazil
Prior art keywords
compounds
preparing
pharmaceutical compositions
muscarinic receptor
urea
Prior art date
Application number
BR0015963-8A
Other languages
English (en)
Inventor
Mathai Mammen
David Oare
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of BR0015963A publication Critical patent/BR0015963A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTOS DE URéIA ANTAGONISTAS DE RECEPTOR MUSCARìNICO, COMPOSIçõES FARMACêUTICAS COMPREENDENDO TAIS COMPOSTOS E MéTODO DE PREPARAçãO DESTES COMPOSTOS". A invenção relata compostos de uréia que são antagonistas de receptor muscarínico e agonistas, composições farmaceuticas compreendendo tais compostos e método de preparação destes compostos.
BR0015963-8A 1999-12-07 2000-12-07 Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos BR0015963A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45617099A 1999-12-07 1999-12-07
PCT/US2000/033155 WO2001042213A1 (en) 1999-12-07 2000-12-07 Urea compounds having muscarinic receptor antagonist activity

Publications (1)

Publication Number Publication Date
BR0015963A true BR0015963A (pt) 2002-08-06

Family

ID=23811737

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015963-8A BR0015963A (pt) 1999-12-07 2000-12-07 Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos

Country Status (27)

Country Link
US (3) US6635764B2 (pt)
EP (2) EP1235803B1 (pt)
JP (1) JP2003516391A (pt)
KR (1) KR100748150B1 (pt)
CN (1) CN1271054C (pt)
AT (2) ATE439345T1 (pt)
AU (1) AU782232B2 (pt)
BR (1) BR0015963A (pt)
CA (1) CA2392030C (pt)
CZ (1) CZ20021830A3 (pt)
DE (2) DE60012223T2 (pt)
EA (1) EA006437B1 (pt)
ES (3) ES2225275T3 (pt)
HK (1) HK1049483B (pt)
HR (1) HRP20020574B1 (pt)
HU (1) HUP0203677A2 (pt)
IL (2) IL149289A0 (pt)
IS (1) IS2191B (pt)
MX (1) MXPA02005602A (pt)
NO (1) NO323544B1 (pt)
NZ (1) NZ518722A (pt)
PL (1) PL364922A1 (pt)
SK (1) SK7982002A3 (pt)
UA (1) UA73543C2 (pt)
WO (1) WO2001042213A1 (pt)
YU (1) YU42402A (pt)
ZA (2) ZA200204553B (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
GB0108099D0 (en) * 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
EA200500173A1 (ru) 2002-07-08 2005-08-25 Рэнбакси Лабораториз Лимитед Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
CN100364990C (zh) * 2002-10-30 2008-01-30 施万制药 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
CN101239971B (zh) * 2003-02-14 2011-07-20 施万制药 联苯衍生物
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1618091A1 (en) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089900A1 (en) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
CA2530376A1 (en) * 2003-06-23 2005-01-06 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
JP2007524641A (ja) * 2003-07-11 2007-08-30 セラヴァンス， インコーポレーテッド 置換４−アミノ−１−ベンジルピペリジン化合物
AR047759A1 (es) * 2003-09-26 2006-02-22 Vertex Pharma Derivados de fenil - piperazina como moduladores de receptores muscarnicos
PE20050973A1 (es) * 2003-10-29 2005-11-19 Theravance Inc Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
WO2005080375A1 (en) * 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7265133B2 (en) * 2004-03-11 2007-09-04 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7262205B2 (en) * 2004-03-11 2007-08-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7560469B2 (en) * 2004-03-11 2009-07-14 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7501442B2 (en) * 2004-03-11 2009-03-10 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087735A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528413A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
EP1758926A4 (en) * 2004-05-21 2008-04-16 Univ California METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER WITH WNT INHIBITORY FACTOR-1 (WIF-1)
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
JP2008510014A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
WO2006045119A2 (en) 2004-10-20 2006-04-27 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
JP2008521821A (ja) 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
GB0503054D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
EP1856049A1 (en) * 2005-03-10 2007-11-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI372749B (en) * 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2008538104A (ja) * 2005-03-10 2008-10-09 セラヴァンス， インコーポレーテッド ムスカリン受容体アンタゴニストとして有用なビフェニル化合物
EP1856112A1 (en) * 2005-03-10 2007-11-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) * 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7786308B2 (en) * 2005-03-28 2010-08-31 Vertex Pharmaceuticals Incorporated Muscarinic modulators
WO2006138218A1 (en) * 2005-06-13 2006-12-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
US7973055B2 (en) * 2006-03-09 2011-07-05 Theravance, Inc. Crystalline forms of a biphenyl compound
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
WO2008096870A1 (ja) * 2007-02-09 2008-08-14 Astellas Pharma Inc. アザ架橋環化合物
EP2222637A1 (en) * 2007-12-14 2010-09-01 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
ES2635358T3 (es) 2009-04-23 2017-10-03 Theravance Respiratory Company, Llc Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
CN103168038A (zh) * 2010-10-20 2013-06-19 奇斯药制品公司 用于治疗咳嗽的碳酸酯衍生物
JP6021616B2 (ja) * 2012-12-04 2016-11-09 株式会社アエタスファルマ ３−ピペラジニル−１−ピペリジニル−プロパン誘導体及びそれを含有してなる医薬組成物
KR101514320B1 (ko) 2013-06-14 2015-04-22 재단법인 의약바이오컨버젼스연구단 신규한 암 예방 또는 치료용 약학적 조성물
MX370140B (es) * 2014-06-06 2019-12-03 Astellas Pharma Inc Derivado de 2-acilaminotiazol o sal del mismo.
MY202833A (en) 2018-05-08 2024-05-24 Nippon Shinyaku Co Ltd Azabenzimidazole compounds and pharmaceutical
WO2020086864A1 (en) * 2018-10-24 2020-04-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2020204548A1 (ko) * 2019-03-29 2020-10-08 재단법인 의약바이오컨버젼스연구단 항암활성을 갖는 신규한 화합물 및 이의 제조방법
MX2022005359A (es) * 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CA3161582A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
DE3402060A1 (de) 1984-01-21 1985-08-01 Dr. Karl Thomae Gmbh, 7950 Biberach Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4675326A (en) 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
DK443489D0 (da) * 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
EP0640081B1 (en) 1992-03-31 2000-01-12 Glaxo Group Limited Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-ht4 antagonists
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
AU685225B2 (en) * 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
US5691323A (en) 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
ATE205490T1 (de) * 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
US6063792A (en) * 1996-07-01 2000-05-16 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (S)-trihexyphenidyl
US6500934B1 (en) 1996-07-24 2002-12-31 Michael Rush Lerner Bivalent agonists for G-protein coupled receptors
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6062766A (en) * 1997-08-04 2000-05-16 Quixote Corporation Raised pavement marker
CA2313125A1 (en) * 1997-12-12 1999-06-24 Laramie Mary Gaster Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
US6086881A (en) * 1998-05-15 2000-07-11 Children's Medical Center Corp. Spatially aligned conjugated composition having a thioether bond linkage
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
ATE299494T1 (de) * 1999-12-07 2005-07-15 Theravance Inc Carbamat-derivate als muscarin-rezeptor antonisten
WO2001098458A2 (en) * 2000-06-19 2001-12-27 Zyomyx, Inc. Methods for immobilizing polypeptides

Also Published As

Publication number Publication date
ES2243333T3 (es) 2005-12-01
ZA200204553B (en) 2003-09-08
NZ518722A (en) 2004-03-26
UA73543C2 (uk) 2005-08-15
IL149289A0 (en) 2002-11-10
PL364922A1 (en) 2004-12-27
NO20022683D0 (no) 2002-06-06
IS6362A (is) 2002-04-26
IL149289A (en) 2007-05-15
CN1271054C (zh) 2006-08-23
WO2001042213A1 (en) 2001-06-14
JP2003516391A (ja) 2003-05-13
US20040054187A1 (en) 2004-03-18
ATE439345T1 (de) 2009-08-15
CA2392030C (en) 2009-08-18
IS2191B (is) 2007-01-15
ES2225275T3 (es) 2005-03-16
AU782232B2 (en) 2005-07-14
CN1407970A (zh) 2003-04-02
EP1457488A1 (en) 2004-09-15
DE60042762D1 (de) 2009-09-24
HK1049483A1 (en) 2003-05-16
US6635764B2 (en) 2003-10-21
NO323544B1 (no) 2007-06-11
DE60012223D1 (de) 2004-08-19
ZA200204557B (en) 2003-09-08
EP1235803B1 (en) 2004-07-14
EP1457488B1 (en) 2009-08-12
KR20020058083A (ko) 2002-07-12
NO20022683L (no) 2002-07-02
CA2392030A1 (en) 2001-06-14
ATE271039T1 (de) 2004-07-15
EP1235803A1 (en) 2002-09-04
EA200200646A1 (ru) 2002-12-26
AU1951801A (en) 2001-06-18
MXPA02005602A (es) 2004-09-10
EA006437B1 (ru) 2005-12-29
HK1049483B (en) 2005-02-18
ES2329785T3 (es) 2009-12-01
KR100748150B1 (ko) 2007-08-09
HRP20020574A2 (en) 2005-08-31
HUP0203677A2 (hu) 2003-03-28
US20040116706A1 (en) 2004-06-17
CZ20021830A3 (cs) 2002-10-16
YU42402A (sh) 2006-01-16
SK7982002A3 (en) 2002-12-03
US20020049195A1 (en) 2002-04-25
DE60012223T2 (de) 2005-08-25
HRP20020574B1 (hr) 2007-12-31

Similar Documents

Publication Publication Date Title
MXPA02005602A (es) Compuestos de urea que tienen actividad antagonista para el receptor muscarinico.
DE60021282D1 (de) Carbamat-derivate als muscarin-rezeptor antonisten
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
TR200101155T2 (tr) 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III
PT1274687E (pt) Derivados de 1,2,3,4-tetra-hidroisoquinolina
NO20015309D0 (no) 1- (P-tienylbenzyl)-imidazoler som antiotensin-(1- 7)reseptoragonister, fremgangsmåte for fremstilling og anvendelseav de samme og farmasöytiske preparater som inneholder nevnteforbindelser
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
UA39168C2 (uk) Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі
WO2000073307A3 (en) Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors
TR199801594A2 (xx) CCR-3 resept�r antagonistleri.
NO20032905D0 (no) Nye benzodiazepiner og beslektede heterocykliske derivater som er anvendelige som orexinreseptorantagonister
BR0016396A (pt) Novos antagonistas do receptor p2x7 para uso no tratamento de doenças inflamatórias, imunes ou cardiovasculares
CL2003001814A1 (es) Compuestos derivados de 1,3,8-triazaespiro[4,5]decan-4-ona jidroxialquil sustituidos, moduladores del receptor orl-1; compuestos intermediarios; composicion farmaceutica que contiene dichos compuestos; procedimiento de preparacion de la composicion f
DE60225174D1 (de) Beta-3 adrenergische agonisten
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
TR200002896T2 (tr) Kalsilitik Bileşimler
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
HUP0103431A3 (en) Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
HUP0200281A3 (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists, process for their preparation and pharmaceutical compositions containing them
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
BR9811821A (pt) 2-acilaminopropanaminas como antagonistas de receptores de taquicinina
WO2001029066A3 (en) Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them
SE9702794D0 (sv) New compounds
ATE279923T1 (de) Urotensin-ii rezeptorantagonisten

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8,13,24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.